Financial Times (7 July 2021)

OTC naloxone is a baby step toward making the life-saving medication accessible Critiquing profiteering by naloxone manufacturers and proposing solutions to fix this issue.

As states start to get opioid settlement cash, few are sharing how they spend it Promoting transparency with opioid settlement money to ensure it goes towards evidence-based solutions.

FDA approves overdose-reversing Narcan for over-the-counter sale Comments on how OTC naloxone isn’t enough to address issues with access.